GlassScriptPhysician profile
Rachel N Kummer
NPI 1548788813
$6,590.12
in general payments reported to CMS, 2019-2025
24 companies · $2,330 in 2025
The $2,330 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $872 · 2023: $1,212 · 2024: $1,689 · 2025: $2,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,819 · Travel and Lodging: $411 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,818.97 |
| Travel and Lodging | $410.85 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $883.53 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $859.50 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $707.04 | 2022-2025 | Avvigo Guidance System, Synergy, Resonate El Icd Vr |
| Merck Sharp & Dohme LLC | $640.97 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $553.61 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $493.03 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $444.14 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $394.11 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $302.46 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Navitor |
| Sanofi-Aventis U.S. LLC | $216.85 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $198.21 | 2021-2025 | Wainua |
| Irhythm Technologies, INC. | $140.88 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.32 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $111.97 | 2024 | Arcalyst |
| Pfizer INC. | $88.70 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.58 | 2023-2025 | |
| Scpharmaceuticals INC. | $76.44 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $54.34 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $53.74 | 2025 | Amvuttra |
| Lantheus Medical Imaging, INC. | $47.70 | 2022 | |
| Astellas Pharma US INC | $44.64 | 2021 | |
| Impulse Dynamics (USA) INC. | $24.29 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $23.57 | 2023 | Inpefa |
| Philips North America LLC | $14.50 | 2024 | (Cm9) Amb Mon & Diag Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.